Proteasome inhibition sensitizes hepatoc
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL
โ
Tom M. Ganten; Ronald Koschny; Tobias L. Haas; Jaromir Sykora; Min Li-Weber; Ker
๐
Article
๐
2005
๐
John Wiley and Sons
๐
English
โ 809 KB
TRAIL exhibits potent anti-tumor activity on systemic administration in mice. Because of its proven in vivo efficacy, TRAIL may serve as a novel anti-neoplastic drug. However, approximately half of the tumor cell lines tested so far are TRAIL resistant, and potential toxic side effects of certain re